Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gypenoside XVII (Gynosaponin S) confers protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, activation of Nrf2/ARE/HO-1 and inactivation of GSK-3β pathways.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 9,500 | |||
5 mg | 在庫あり | ¥ 21,500 | |||
10 mg | 在庫あり | ¥ 33,500 | |||
25 mg | 在庫あり | ¥ 60,000 | |||
50 mg | 在庫あり | ¥ 89,000 | |||
100 mg | 在庫あり | ¥ 132,000 |
別名 | GP-17, Gynosaponin S |
分子量 | 947.15 |
分子式 | C48H82O18 |
CAS No. | 80321-69-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (63.35 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Gypenoside XVII 80321-69-3 Endocrinology/Hormones Metabolism PI3K/Akt/mTOR signaling Stem Cells GSK-3 Estrogen Receptor/ERR Endogenous Metabolite inhibit GP-17 Gynosaponin S GP17 GP 17 Inhibitor inhibitor